FDA has until May 25, 2026 to object to the notification, after which the Company will be free to market its proposed dietary supplement containing Australian Chestnut Extract Company has signed an option...
All three patients enrolled in study have been cured, confirming high cure rate of tafenoquine in immunosuppressed patients, as reported by Yale in a 2024 publication Company calls for existing babesiosis...
ORLANDO, FL / ACCESS Newswire / February 27, 2026 / RedChip Companies will air interviews with 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP) and BioVie, Inc. (NASDAQ:BIVI) on the RedChip Small Stocks,...
GoodRx to offer prescription savings of up to 30% for ARAKODA ® ( tafenoquine ) Collaboration designed to lower patient out-of-pocket costs and expand the reach of Company’s marketing strategy Partnership...
WASHINGTON, Jan. 28, 2026 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (“60 Degrees Pharma” or the “Company”), a pharmaceutical company focused on developing...
Partnership adds a travel-focused consumer telehealth platform to the ARAKODA ® marketing strategy, offering a new convenience to people planning travel to malaria-endemic regions of the world ARAKODA...
WASHINGTON, Jan. 15, 2026 (GLOBE NEWSWIRE) -- 60 Degree Pharmaceuticals, Inc. NASDAQ: SXTP; SXTPW) (“60 Degrees Pharma” or the “Company”), a pharmaceutical company focused on developing new medicines...
Further validates continuation of the B-FREE Study to evaluate the efficacy and safety of ARAKODA ® ( tafenoquine ) for treatment of chronic babesiosis Data support theory among specialists that Babesia...
ORLANDO, FL / ACCESS Newswire / December 26, 2025 / RedChip Companies will air interviews with Processa Pharmaceuticals, Inc. (Nasdaq:PCSA) and 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP) on the RedChip...
6-month commercial pilot demonstrated increasing demand among prescribers Expansion plan includes doubling the number of sales reps, a new GoodRx partnership, and enhanced digital marketing campaign ...